Victor F. C. Raczkowski, M.D., M.S., Named Vice President of U.S. Regulatory Affairs for Solvay Pharmaceuticals, Inc.
Marietta, Ga.(March 26, 2007) — Solvay Pharmaceuticals, Inc. announced today that Victor F. C. Raczkowski, M.D., M.S., has been named vice president of U.S. Regulatory Affairs. In this role, Raczkowski will provide regulatory leadership and direction for the U.S. commercial business, assure U.S. regulatory compliance, and be responsible for all activities and interactions associated with the U.S. Food and Drug Administration (FDA). He will serve as a member of Solvay Pharmaceuticals’ Global Regulatory Affairs Leadership Team, the U.S. Pharmaceutical Leadership Team, the U.S. Compliance Committee and the U.S. Labeling Review Committee.
Prior to joining Solvay Pharmaceuticals, Raczkowski was vice president of Regulatory Affairs at Cephalon, Inc. in Frazer, Pa. Having worked at the FDA for 13 years, he has extensive experience in a variety of senior leadership positions at the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).
Additionally, he has been published in a variety of medical journals including Circulation, the European Journal of Pharmacology, and Clinical Chemistry, and has lectured at numerous meetings and symposia nationwide.
Raczkowski graduated with a bachelor’s degree in chemistry from Swarthmore College in Swarthmore, Pa., received a master of science degree in pharmacology from The University of Chicago in Chicago, Ill. and earned a doctor of medicine degree from Rush Medical College in Chicago, Ill. He completed his residency in pediatrics and fellowship training in pediatric cardiology from the Children’s Hospital National Medical Center in Washington, DC.
About Solvay Pharmaceuticals
Solvay Pharmaceuticals, Inc., of Marietta, Georgia is the U.S. subsidiary of Solvay Pharmaceuticals. For more information, visit www.solvaypharmaceuticals-us.com.
Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, gastroenterology and men’s and women’s health. Its 2006 sales were EUR 2.6 billion and it employs approximately 10,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.
SOLVAY is an international chemical and pharmaceutical group with headquarters in Brussels. It employs some 30,000 people in 50 countries. In 2006 its consolidated sales amounted to EUR 9.4 billion, generated by its three activity sectors: Chemicals, Plastics and Pharmaceuticals. SOLVAY (Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the Euronext stock exchange in Brussels. Details are available at www.solvay.com.
